Guardant Health Reports the Submission of Premarket Approval Application to the US FDA for Shield Blood Test to Detect Colorectal Cancer
Shots:
- The company has submitted the premarket approval application to the US FDA for the Shield blood test. The submission was based on the (ECLIPSE) study evaluating the performance of Shield blood test over screening colonoscopy in ~20,000 avg.-risk adults aged 45 & 84yrs. at 200+ clinical trial sites in rural & urban communities across 34 states
- Acc. to preliminary results, the Shield test had a sensitivity of 83% & a specificity of 90% for the detection of colorectal cancer. The test also demonstrated 13% sensitivity in detecting advanced adenomas
- The test identifies specific DNA characteristics that may indicate the presence of cancer & is commercially available only on prescription through healthcare providers for eligible individuals
Ref: Guardant Health | Image: Guardant Health
Related Post:- Guardant Health Collaborated with AnHeart Therapeutics to Develop Guardant360 CDx and Guardant360 TissueNext for Taletrectinib
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
